iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
iECURE has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
iECURE's investors include Novo Holdings, OrbiMed, LYFE Capital, Versant Ventures.
iECURE is headquartered in Philadelphia, United States.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
iECURE is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iECURE — Funding & Investors." VCBacked, November 30, 2022, https://www.vcbacked.co/company/iecure. Accessed August 8, 2026.
VCBacked. (2022). iECURE — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/iecure
{{cite web |title=iECURE — Funding & Investors |url=https://www.vcbacked.co/company/iecure |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated